Related references
Note: Only part of the references are listed.Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus
Wenying Shu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population
Wen-ying Shu et al.
ACTA PHARMACOLOGICA SINICA (2015)
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
Fritz Offner et al.
BLOOD (2015)
Prednisone Has No Effect on the Pharmacokinetics of CYP3A4 Metabolized Drugs - Midazolam and Odanacatib
Eugene E. Marcantonio et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database
D-P Dai et al.
PHARMACOGENOMICS JOURNAL (2014)
Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation
S. Martis et al.
PHARMACOGENOMICS JOURNAL (2013)
MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines
Yousuke Uchida et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Potential Contribution of Cytochrome P450 2B6 to Hepatic 4-Hydroxycyclophosphamide Formation In Vitro and In Vivo
Brianne S. Raccor et al.
DRUG METABOLISM AND DISPOSITION (2012)
The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status
Nuala Helsby et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
A. Smith et al.
BRITISH JOURNAL OF CANCER (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Simultaneous determination of cyclophosphamide and 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry - application to Chinese systemic lupus erythematosus patients
Wenying Shu et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
Analysis of CYP3A4 genetic polymorphisms in Han Chinese
Qing Zhou et al.
JOURNAL OF HUMAN GENETICS (2011)
Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach
Andrew S. Moore et al.
JOURNAL OF PAEDIATRICS AND CHILD HEALTH (2011)
Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation
Stacy E. F. Melanson et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
J. Bray et al.
BRITISH JOURNAL OF CANCER (2010)
The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation
Nuala A. Helsby et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes
Jennifer B. Dennison et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Aberrant splicing caused by single nucleotide polymorphism c.516G> T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver
Marco H. Hofmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Influence of polymorphisms of drug metabolizing enzymes (CYP2136, CYP2C9, CYPX19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide
Corine Ekhart et al.
PHARMACOGENETICS AND GENOMICS (2008)
Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7
Margalida Rotger et al.
PHARMACOGENETICS AND GENOMICS (2007)
Polymorphic CYP2B6:: molecular mechanisms and emerging clinical significance
Ulrich M. Zanger et al.
PHARMACOGENOMICS (2007)
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients
Miki Nakajima et al.
PHARMACOGENETICS AND GENOMICS (2007)
Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes
Jennifer B. Dennison et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals
M. Rotger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Global variation in copy number in the human genome
Richard Redon et al.
NATURE (2006)
Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction
Sharon L. Ripp et al.
DRUG METABOLISM AND DISPOSITION (2006)
Determinants of the rate of nicotine metabolism and effects on smoldng behavior
Elaine Johnstone et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Genetic polymorphisms of cytochrome P4502B6 gene in Han Chinese
Su Guan et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Intra- and inter-ethnic differences in the allele frequencies of cytochrome P4502B6 gene in Chinese
Su Guan et al.
PHARMACEUTICAL RESEARCH (2006)
Structural variants: changing the landscape of chromosomes and design of disease studies
L Feuk et al.
HUMAN MOLECULAR GENETICS (2006)
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies
HJ Xie et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer
WP Petros et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population
YF Hu et al.
CLINICA CHIMICA ACTA (2005)
SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci
YY Shi et al.
CELL RESEARCH (2005)
Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P4502C19
R Timm et al.
PHARMACOGENOMICS JOURNAL (2005)
Genetic polymorphism of cytochrome P4502C19 in healthy Malaysian subjects
YS Yang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Large-scale copy number polymorphism in the human genome
J Sebat et al.
SCIENCE (2004)
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis
K Takada et al.
ARTHRITIS AND RHEUMATISM (2004)
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
J Kirchheiner et al.
PHARMACOGENETICS (2003)
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma
JK Doorduijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Bioactivation of cyclophosphamide:: the role of polymorphic CYP2C enzymes
L Griskevicius et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation
HJ Xie et al.
PHARMACOGENOMICS JOURNAL (2003)
Clinical significance of the cytochrome P4502C19 genetic polymorphism
Z Desta et al.
CLINICAL PHARMACOKINETICS (2002)
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
T Lang et al.
PHARMACOGENETICS (2001)
Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide
ZQ Huang et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Share Paper
